Product Description
AbbVie is developing ABBV-47D11 as a treatment for COVID-19. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04644120)
Mechanisms of Action: ACE Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: COVID-19
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04644120 |
M20-404 | P1 |
Completed |
COVID-19 |
2021-08-24 |
34% |
2021-09-03 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/22/2021 |
News Article |
COVID-19 Pipeline Insight Report, Q2 2021 Edition - ResearchAndMarkets.com |
|
12/14/2020 |
News Article |
Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials |